GlassScriptPhysician profile
Shilpa Pakala
NPI 1851412696
$1,425.48
in general payments reported to CMS, 2019-2025
12 companies · $211 in 2025
The $211 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $606 · 2020: $145 · 2021: $78.81 · 2022: $55.46 · 2023: $98.78 · 2024: $230 · 2025: $211.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $540.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $539.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $263.20 | 2021-2024 | Wegovy, Ozempic, Rybelsus |
| Abbvie INC. | $244.99 | 2019-2025 | |
| Gilead Sciences, INC. | $144.56 | 2019-2020 | |
| Neurocrine Biosciences, INC. | $125.00 | 2019 | |
| Amarin Pharma, INC. | $125.00 | 2019 | |
| Merck Sharp & Dohme LLC | $124.58 | 2019 | |
| Amgen INC. | $91.24 | 2025 | Evenity |
| Vertiflex, INC. | $87.20 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $80.07 | 2020-2022 | |
| Inspire Medical Systems, INC. | $71.82 | 2024 | Inspire |
| Endogastric Solutions, INC | $51.89 | 2023 | Esophyx |
| Dexcom, INC. | $15.93 | 2024 | Dexcom G6 Transmitter |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Shilpa Pakala listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.